Big pharma bet: Jefferies lists out India’s next CRDMO multibaggers with up to 37% upside
The Indian CRDMO industry is a key player for global pharma companies, with a market value of $40-50 billion. Jefferies suggests investing in top stocks like Sai Life Sciences, Cohance, and Divi's due to their promising growth prospects. The sector is expected to see revenue growth thanks to the China+1 trend and the increasing GLP-1 drug pipeline.